Sai Parenterals Intrinsic Value
SAIPARENT · NSEValuation
Blended fair value using DCF and peer comparison methods.
Sai Parenterals Intrinsic Value Analysis
The latest available EOD closing price for Sai Parenterals (SAIPARENT) is ₹524 per share. Stored data does not currently provide a positive intrinsic-value estimate for this page.
Current stored data does not provide a usable DCF or peer fair value.
How Understock Calculates Intrinsic Value
Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. When neither method has a usable value, the page reports that an estimate is unavailable. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.
Review this company's DCF valuation · Learn how DCF works · Use the DCF calculator · See Sai Parenterals peer valuation · What intrinsic value means
The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.
Sai Parenterals Peer Comparison
How this company stacks up against sector peers on valuation and quality metrics.
Healthcare · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Sai Parenterals SAIPARENT · you | ₹2,267 Cr | — | — | — | — | 0.2% | — |
| Sector median | — | 43.0× | 6.6× | 21.3× | 12.6% | 3.2% | 10.2% |
| Dr. Agarwal's Health Care Limited AGARWALEYE | ₹16,045 Cr | 349.0× | — | — | — | 0.0% | — |
| Alembic Pharmaceuticals Limited APLLTD | ₹15,334 Cr | 24.2× | 2.9× | 15.6× | 11.9% | 9.2% | 9.1% |
| Park Medi World Limited PARKHOSPS | ₹12,549 Cr | 40.9× | 6.0× | 27.2× | 12.8% | 15.4% | 10.2% |
| Akums Drugs and Pharmaceuticals Limited AKUMS | ₹12,161 Cr | 45.1× | 3.5× | 20.9× | 7.7% | 5.9% | 6.0% |
| Thyrocare Technologies Limited THYROCARE | ₹9,929 Cr | 60.9× | 20.7× | — | 34.0% | 0.2% | — |
| Jupiter Life Line Hospitals Limited JLHL | ₹9,880 Cr | 53.4× | 6.7× | 29.1× | 12.6% | 12.9% | 18.9% |
| Procter & Gamble Health Limited PGHL | ₹9,850 Cr | 27.6× | 16.1× | — | 58.5% | 0.3% | — |
| Healthcare Global Enterprises Limited HCG | ₹8,780 Cr | 638.1× | 6.6× | 21.3× | 1.0% | 0.5% | 14.5% |
Sai is fairly valued relative to sector peers — trading near the sector median on key multiples (P/E ~43.0×, EV/EBITDA ~21.3×). Focus on execution quality and earnings trajectory from here.
Business quality
Valuation
Returns
Growth
Efficiency
Liquidity & Solvency
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.